BiotechTube

IMGN151 + Carboplatin + Bevacizumab + Olaparib

Phase 2Recruiting
0 views this week 0 watching⚡ Active
Interest: 42/100
42
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gynecologic Cancers

Conditions

Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer (PSOC)

Trial Timeline

Jul 30, 2025 → Feb 1, 2028

NCT ID
NCT07024784

About IMGN151 + Carboplatin + Bevacizumab + Olaparib

IMGN151 + Carboplatin + Bevacizumab + Olaparib is a phase 2 stage product being developed by AbbVie for Gynecologic Cancers. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07024784. Target conditions include Gynecologic Cancers, Platinum-Sensitive Ovarian Cancer, Fallopian Tube Cancer.

What happened to similar drugs?

0 of 2 similar drugs in Gynecologic Cancers were approved

Approved (0) Terminated (0) Active (2)
🔄Ciprofol + PropofolHaisco Pharmaceutical GroupPhase 3
🔄FlosealBaxterPhase 3

Hype Score Breakdown

Clinical
12
Activity
15
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT07024784Phase 2Recruiting

Competing Products

13 competing products in Gynecologic Cancers

See all competitors
ProductCompanyStageHype Score
Durvalumab + TremelimumabAstraZenecaPhase 1
21
PembrolizumabMerckPhase 1
29
Atezolizumab + RucaparibRochePhase 1
29
Vigil + AtezolizumabRochePhase 2
35
darbepoetin alfa + recombinant human erythropoietin (rHuEPO)AmgenPhase 2
35
Oral apixaban + Subcutaneous enoxaparinBristol Myers SquibbPhase 2
35
AK112AkesoPhase 2
35
Ciprofol + PropofolHaisco Pharmaceutical GroupPhase 3
40
FlosealBaxterPhase 3
33
FloSeal applicationBaxterPre-clinical
23
IPH2201Innate PharmaPhase 1
19
Neoantigen specific TCR-T cell drug product + Aldesleukin (IL-2)Alaunos TherapeuticsPhase 1/2
14
Neoantigen specific TCR-T cell drug productAlaunos TherapeuticsPre-clinical
16